The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Wolverine Stack

BPC-157 + TB-500 Stack · Wolverine Peptide Stack

C
Animal replicated
Research chemicalPeptide StackRecovery StackConnective-Tissue Support
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
BPC-157 + TB-500 — Community Recovery Peptide Stack — Peptide Stack, Recovery Stack, Connective-Tissue Support.
Why people use it
Used primarily for tissue repair and healing and muscle and performance.
What the evidence supports
No published controlled human trial exists for the BPC-157 + TB-500 combination. The stack evidence is component-level and preclinical/community-derived; the combination itself has zero published studies.
If you only read one thing

The Wolverine Stack is the most widely used peptide healing combination in community history — thousands of user logs, years of accumulated experience, clinics prescribing it, physicians writing protocols for it. The mechanistic rationale is coherent: two compounds, two different mechanisms, two different phases of the healing cascade, administered together. And yet: BPC-157 has 36 published studies — 35 preclinical, 1 clinical. TB-500 + BPC-157 together have zero published studies of any kind. Zero. The combination that community members have been running for years has never been tested in even a mouse model as a combination. The stackGrade is C — not because the combination evidence is weak, but because the combination evidence does not exist. This chapter documents the mechanistic logic, the individual evidence bases, and what thousands of users have reported — with honest evidence framing throughout.

Check interactions →
Published literature
0human trials0human studies0animal0in vitro
Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
0 lab signals
0 animal; 0 in-vitro/mechanistic.
Evidence snapshot
No published controlled human trial exists for the BPC-157 + TB-500 combination. The stack evidence is component-level and preclinical/community-derived; the combination itself has zero published studies.
From the chapter quick-reference block.
Categories
Healing & RecoveryMuscle & PerformanceGut & Digestive
Properties
Active malignancy: cautionInjectable: extrapolated
Evidence
CAnimal replicated
Stack Type
Community healing combination. Not FDA-approved. Not a drug. Research chemical combination protocol. Type: stack. Slug: wolverine-stack. stackGrade: C. Component slugs: bpc-157, tb-500. Related stacks: glow-stack, klow-stack, gut-stack.
Stack Indication
Accelerated systemic healing from acute injury, surgery, or chronic overuse — particularly tendons, ligaments, joints, muscle, and gut. Secondary: recovery optimization in high-load athletes, post-surgical support, systemic tissue maintenance.
Components
BPC-157 (Body Protection Compound 157): synthetic pentadecapeptide derived from human gastric juice protein; SubQ or oral; local angiogenesis, growth factor upregulation, gut protection. Grade C (animal), E (community). | TB-500 (Thymosin Beta-4 fragment, Tβ4[17-23]): heptapeptide LKKTETQ; SubQ; systemic cell migration, actin regulation, anti-inflammation, progenitor cell mobilization. Grade C (parent compound animal); note TB-500 is a fragment — most mechanistic evidence is for full Thymosin Beta-4.
Stack Evidence Grade
C for the combination — the lowest grade of any individual component (both C/E), applied to the combination that has zero controlled studies of any kind. A stack of two Grade C compounds with no combination evidence is not a Grade B stack. The combination evidence grade is C.
Community Protocol
BPC-157: 250-500 mcg/day SubQ (or oral for gut). TB-500: 2-5 mg twice weekly (loading), 2-5 mg once weekly (maintenance). Cycle: 4-8 weeks. Rest: 4+ weeks. Blended vial option: 10mg BPC-157 + 10mg TB-500 per vial — most convenient but reduces independent dosing control.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Gut Peptide Stack
C
Same class · Peptide Stack

Scope appropriateness is the question: local gut peptides are being stacked for barrier integrity and inflammatory signaling, not for systemic regeneration claims.

KLOW Stack
C
Same class · Peptide Stack

Adds KPV’s local gut anti-inflammatory signal to the GLOW recovery-and-skin stack.

CIT Stack
C
Same class · Peptide Stack

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

Check interactions